|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
From the Southwest Oncology Group, San Antonio,
TX.
Cyclosporine A (CsA) inhibits P-glycoprotein (Pgp)-mediated
cellular export of anthracyclines at clinically achievable
concentrations. This randomized controlled trial was performed to test
the benefit of CsA addition to treatment with cytarabine and
daunorubicin (DNR) in patients with poor-risk acute myeloid leukemia
(AML). A total of 226 patients were randomly assigned to sequential
treatment with cytarabine and infusional DNR with or without
intravenous CsA. Remitting patients received one course of
consolidation chemotherapy that included DNR with or without CsA as
assigned during induction. Addition of CsA significantly reduced the
frequency of resistance to induction chemotherapy (31% versus 47%,
P = .0077). Whereas the rate of complete remission was
not significantly improved (39% versus 33%, P = .14),
relapse-free survival (34% versus 9% at 2 years,
P = .031) and overall survival (22% versus 12%,
P = .046) were significantly increased with CsA. The
effect of CsA on survival was greatest in patients with moderate or
bright Pgp expression (median 12 months with CsA versus 4 months for
controls) compared to patients with absent or low Pgp expression
(median 6 months in both arms). The frequency of induction deaths was 15% with CsA and 18% in controls. Steady-state serum concentrations of DNR (P = .0089) and daunorubicinol
(P < .0001) were significantly higher in CsA-treated
patients. Survival (P = .0003) and induction response
(P = .028) improved with increasing DNR concentration in
CsA-treated patients but not in controls, suggesting a targeted interaction by CsA to enhance anthracycline cytotoxicity. These results
indicate that addition of CsA to an induction and consolidation regimen
containing infusional DNR significantly reduces resistance to DNR,
prolongs the duration of remission, and improves overall survival in
patients with poor-risk AML.
(Blood. 2001;98:3212-3220) P-glycoprotein (Pgp) is a highly conserved
170-kd plasma membrane protein that displays structural homology to
bacterial transport proteins.1,2 In human leukemias and
other malignancies, Pgp functions as an adenosine triphosphate
(ATP)-dependent multidrug exporter with broad specificity for natural
product-derived antineoplastics.3 Overexpression of Pgp is
associated with reduced cellular accumulation and relative in vitro
resistance to anthracyclines that can be overcome by concurrent
exposure to Pgp antagonists such as cyclosporine A
(CsA).4-6 In acute myeloid leukemia (AML), Pgp
overexpression is associated with a lower rate of complete remission
(CR) and inferior disease-free and overall survival (OS) in patients
receiving conventional anthracycline-containing induction and
consolidation regimens.7-12
Cyclosporine A is a potent competitive inhibitor of Pgp transport
function at concentrations ranging from 1000 to 2000 ng/mL. In a pilot
study performed in patients with poor-risk AML, coadministration of CsA
and infusional daunorubicin (DNR) yielded a high rate of CR and
eliminated MDR1-overexpressing clones in relapse
specimens.13 Although dose-limiting toxicity was not
encountered, treatment with CsA delayed the hepatic elimination
of bilirubin and DNR, resulting in reversible conjugated
hyperbilirubinemia and increased systemic anthracycline
exposure.13,14
To test whether CsA enhances the antileukemia effect of anthracyclines,
the Southwest Oncology Group (SWOG) conducted a randomized clinical
trial comparing treatment outcomes of adult patients with high-risk AML
or myelodysplastic syndrome (MDS) treated with a DNR- and
cytarabine-containing induction and consolidation chemotherapy regimen
with or without the addition of CsA.
Eligibility
Study design
There was no adjustment of chemotherapy dosage for hematologic toxicity. Treatment with DNR with or without CsA on day 6 was delayed up to 48 hours if serum bilirubin level exceeded 3 times the IULN. Protocol-directed therapy was discontinued if bilirubin level persisted above 3 times the IULN after 48 hours. Neither DNR nor CsA dosage was adjusted or interrupted for elevations in serum bilirubin level resulting from CsA administration. AraC was immediately discontinued for patients developing grade 2 or higher central nervous system toxicity, and treatment with DNR with or without CsA initiated on the following treatment day. Toxicity was graded using standard SWOG toxicity criteria.17 Criteria for response Response was evaluated according to SWOG criteria as modified from National Cancer Institute guidelines.15 OS was measured from the date of randomization until death from any cause. Relapse-free survival (RFS) was measured from the date of CR until relapse or death from any cause, with observation censored at the date of last contact for patients last known to be alive without report of relapse. Patients who failed to achieve CR after induction therapy were classified according to type of failure: resistant disease (RD), death during aplasia, or indeterminate.15Flow cytometric detection of Pgp Blasts from pretreatment bone marrow or peripheral blood were enriched by density gradient separation. Expression of Pgp was measured using the MDR1 specific antibody, MRK16 (Kamiya, Thousand Oaks, CA) in 3-color flow cytometry assays in which blasts were costained with MRK16, the hematopoietic stem/progenitor cell antigen CD34, and the panmyeloid antigen CD33, as previously described.10,18 Analyses were performed using an isotype control on a FACScan flow cytometer using Lysis II software (Becton Dickinson). Expression of Pgp on gated leukemic blasts compared to control cells was measured using a modification of the Kolmogorov-Smirnov statistic, denoted D, which measures the difference between 2 distribution functions and generates a value ranging from 0 to 1.0.19 The method was modified by ascribing a negative value to cases where the median fluorescence intensity of the control cells was brighter than that of antibody-stained cells.10,18 MRK16 staining intensity was categorized for descriptive purposes as follows: moderate or bright (D > 0.20 [Pgp+]), dim and negative (D < 0.20 [Pgp ]); however, analyses of clinical outcomes
in relation to Pgp expression were performed using the D value as a
continuous variable. Figure 1 provides
representative flow histograms illustrating the range of Pgp expression
detected in patient leukemia specimens and corresponding control
cell lines.
Daunorubicinol pharmacokinetics Serum samples were obtained from a peripheral venous source just prior to the completion of the DNR infusion on induction day 9 (ie, estimate of DNR steady-state serum concentration), and 24 hours later (day 10) on all study patients.13 A reference (pre-DNR) sample was obtained just before initiation of chemotherapy on day 1. Serum samples were cryopreserved and stored at 80°C before being
thawed and DNR and daunorubicinol (DNR-ol) concentration analyzed by
reverse-phase high-pressure liquid chromatography (HPLC) using a method
modified after Peng and coworkers20 as previously
described.13 Measurements below limits of detection (10 and 5 ng/dL for DNR and DNR-ol, respectively) were included in analyses
as censored observations.
Whole-blood CsA concentration EDTA-anticoagulated blood obtained from a peripheral venous source was obtained from patients assigned to treatment with CsA on day 6 of induction therapy immediately before administration of the 24-hour infusions of CsA and DNR. Specimens were cryopreserved and stored at80°C before being thawed and centrally analyzed by radioimmunoassay
as previously described.13
Serum sensitization assay The ability of day 6 patient serum to enhance DNR cytotoxicity in the Pgp+ myeloma cell line, 8226/Dox6, was evaluated using a microculture dye reduction assay.21 Cryopreserved patient serum obtained immediately prior to DNR administration was thawed, and aliquots of patient or volunteer (control) serum were incubated with 8226/Dox6 cells for 10 minutes prior to the addition of DNR (0.1-50 µg/mL) and incubated for 1 hour at 37°C. Cells were then washed twice and plated in triplicate in 96-well microtiter plates. Cell viability was determined by assessment of dye fluorescence using 3-[4,5-dimethylthiazol-2-yl]-2,5diphenyltetrazolium bromide in the methyl-thiazol-diphenyl-tetrazolium (MTT) assay after a 4-day incubation.21 The magnitude of enhancement of DNR cytotoxicity in Dox6 cells (ie, sensitization factor) was determined by dividing the DNR concentration, which yielded a 50% reduction in cell viability (IC50) in 8226/Dox6 cells incubated with control serum (CsA) by the IC50 obtained from cells incubated with patient serum (+CsA).
Cytogenetic analysis Cytogenetic studies were performed using standard G-banding with trypsin-Giemsa or trypsin-Wright staining in SWOG-approved cytogenetics laboratories. Karyotypes were interpreted using International System for Cytogenetic Nomenclature (ISCN) criteria.22 Karyotypes were considered normal diploid if no clonal abnormalities were detected in a minimum of 20 metaphases examined and if 2 growth/harvesting methods were used. Each karyotype was independently reviewed by at least 2 members of the SWOG Cytogenetics Committee. Karyotypic abnormalities were grouped into prognostic categories based on published literature for correlation with clinical outcome.10,23-26 Karyotypes that could not be assigned to risk categories were regarded as not classified.Statistical analysis The study design called for randomization of 220 eligible patients, providing statistical power of 82% to detect a 50% increase in the CR rate from 35% to 53% (one-tailed test at 5% critical level). This would also provide 90% power to detect a mortality hazard ratio (CsA to control) of 0.67, assuming patient accrual over 66 months, 6 additional months' follow-up, and median OS of 6 months for controls. This study was monitored throughout its accrual and follow-up phases by a Data and Safety Monitoring Committee of which the investigators were not members. Two interim analyses were performed but did not require modification or early termination of the study.Treatment comparisons were based on assigned treatments, that is, CsA-assigned patients who did not receive CsA were retained in the CsA arm. CR and RD rates were analyzed using the Fisher exact test and logistic regression analysis.27 Distributions of OS and RFS were estimated by the method of Kaplan and Meier, and analyzed according to treatment assignment and patient and disease characteristics using proportional hazards regression models.28,29 Wilcoxon rank sum test and its generalization for censored data were used for comparisons of quantitative variables such as Pgp expression level or DNR and DNR-ol concentrations. Because the principal objective of the study was to assess whether CsA improves treatment outcomes, the statistical significance of treatment differences in outcomes was measured by one-sided P values for superior outcome in the CsA arm. All other test results are reported using 2-sided P values. Results are based on data available November 19, 1999.
Patients and randomization Among 231 patients registered for study treatment between March 1993 and March 1998, 5 were ineligible due to excluded diagnoses (4 patients) or abnormal liver function (1 patient). Of 226 eligible patients, 107 patients were randomized to treatment with AraC-DNR and 119 to treatment with AraC-DNR+CsA. The distributions of age, gender, and diagnosis were similar in the 2 treatment groups (Table 1). Approximately 75% of patients in each treatment arm had relapsed or refractory AML; the remaining had untreated secondary AML or RAEB-t. The proportion with unfavorable karyotypes was somewhat lower in the CsA arm (36 of 85, 42%) compared to the controls (42 of 78, 54%). Among 197 patients with adequate specimens for Pgp analysis, approximately one third in each arm had moderate or bright Pgp expression. The proportion of Pgp+ patients was somewhat higher in the previously untreated group (48%) compared to the relapsed/refractory group (31%), although the difference in Pgp expression levels was not statistically significant (P = .12 by Wilcoxon rank sum test).
Induction outcome and survival Among the eligible patients randomized, 118 (99%) patients assigned treatment with CsA and 105 (98%) controls received their protocol-directed therapy. Forty-seven of the 119 eligible CsA patients achieved CR (39%, 95% confidence interval [CI], 31%-48%), compared to 35 of the 107 controls (33%, CI, 24%-42%; P = .14; Table 2). A significantly greater proportion of patients treated with CsA achieved CR after one course of induction therapy (38%, 45 of 119; CI, 29%-47%) compared to the controls (26%, 28 of 107; CI, 18%-34%; P = .032). Only 2 (4%) of the 47 CsA patients required 2 courses of induction therapy compared to 7 (20%) of the 35 controls (P = .024). Median time from the start of treatment to achievement of CR was 48 days (range, 24-98 days) with CsA and 52 days (range, 24-419 days) for controls. Among the 51 patients with indeterminate or inadequately assessed response according to the NCI guidelines,15 10 (7 CsA, 3 control) were considered probable complete responders because they survived at least 90 days and achieved either normal marrow or peripheral blood examinations. The proportion of documented or probable CRs was 45% (CI, 36%-54%) with CsA and 36% (CI, 26%-45%) for controls (P = .065). Treatment with CsA was associated with a significant reduction in the frequency of RD: 37 of 119 (31%, CI, 23%-39%) with CsA versus 50 of 107 (47%, CI, 37%-56%) among controls (P = .0077).
Fifty-seven remitting patients (30 CsA, 27 controls) received
protocol-directed consolidation chemotherapy. RFS (Figure
2) among all 82 remitting patients was
significantly higher in the CsA arm (P = .031). The
estimated probability of RFS at 2 years was 34% (CI, 20%-48%) with
CsA compared to 9% (CI, 0%-18%) for controls (relative risk [RR],
0.59; CI, 0.34-1.03). OS was significantly improved in the CsA arm (RR,
0.78; CI, 0.58-1.04; P = .046), with estimated 2-year
survival of 22% (CI, 14%-30%) compared to 12% (CI, 6%-18%) for
controls (Figure 3). There was no
significant difference in the benefit of CsA treatment between patients
who had received prior chemotherapy (ie, relapsed and refractory) and
those previously untreated (ie, secondary AML and RAEB-t): CR,
P = .66; RD, P = 0.76 (Tables
3 and
4); OS, P = .057 and RFS, P = .26 (Figure
4). The marginally significant
interaction between the effects of prior treatment and CsA on OS is
largely attributable to the particularly poor survival among the
22 control patients with untreated secondary AML or RAEB-t; all
22 of whom succumbed to disease within 2 years (median OS, 4 months; CI, 1-7 months), compared to a median OS of 9 months (CI, 6-13 months) among the 27 previously untreated CsA patients.
Among remitting patients under age 60 at study entry, 9 of 25 controls (36%) and 17 of 39 CsA patients (43%) received stem cell transplants in remission. In an analyses of RFS limited to this age group, the estimated RR comparing patients after receiving their transplants to patients not receiving transplants was 0.70 (CI, 0.34-1.46). This indicates that the risk of relapse or death was somewhat lower following transplantation, though not statistically significant. Therefore, we investigated whether the apparent benefit of CsA might be attributable to the slightly higher proportion of patients receiving transplants in the CsA arm. In a proportional hazards regression model that allowed the prognosis for RFS to improve following transplantation, the resulting adjusted estimate of the treatment RR was 0.42 (CI, 0.22-0.81). This is nearly identical to the estimate of 0.44 (CI, 0.23-0.84) obtained without adjusting for the effect of transplantation, suggesting that the CsA effect was not attributable to transplantation in remission. Effect of Pgp and cytogenetic pattern Among all study patients, treatment response and OS did not vary markedly in relation to myeloblast expression of Pgp (Pgp+ versus Pgp: CR, 37% versus 36%; RD, 37% versus 42%;
median OS, 8 versus 6 months), although RFS was rather better in the
Pgp+ group (median, 15 versus 6 months,
P = .050). Response to induction chemotherapy according to
Pgp expression and treatment arm is summarized in Table
5. Although these data suggest that the
benefit of CsA was somewhat greater in Pgp+ patients, the
treatment effect did not vary significantly over the range of Pgp
expression analyzed (test for interaction: CR, P = 0.61;
RD, P = .83). OS was also analyzed in relation to blast expression of Pgp and treatment arm (Figure
5). Median survival in Pgp+
patients was 12 months (CI, 7-19 months) in CsA-treated patients, but
only 4 months in controls (CI, 2-6 months). Among Pgp
patients, in contrast, median OS was 6 months (CI, 4-8 months) in both
treatment arms; however, the treatment difference did not vary
significantly over the range of Pgp expression levels (interaction
P = .63). A similar pattern was seen for RFS, with medians
of 17 and 7 months (CIs 7-52 and 4-15 months) for CsA-treated Pgp+ and Pgp patients, respectively, and 7 and 5 months (CIs 5-9 and 3-9 months) for Pgp+ and
Pgp controls (interaction P = .21).
Response and OS varied significantly between the favorable,
intermediate, and unfavorable cytogenetic groups (CR,
P = .0080; RD, P = .016; OS,
P = .0001; RFS, P = .18). For example,
estimated survival at 2 years was 44% (CI, 21%-68%), 18% (95% CI,
9%-27%), and 12% (95% CI, 5%-19%) for patients with a favorable,
intermediate, and unfavorable karyotype, respectively. Additional
analyses were performed to determine whether imbalance in distribution
of cytogenetic patterns between the treatment arms might explain the
apparent benefit of CsA. After adjusting for differences between the
cytogenetic groups (Table 5), CsA continued to be associated with a
nonsignificant increase in CR rate (P = .086), a
significant decrease in RD (P = .019), and significantly
improved OS (P = .013) with an estimated RR of 0.68 (CI,
0.49-0.96) (Figure 6A,B). CsA treatment
was associated with a similar improvement in RFS after adjustment for
cytogenetic pattern (RR, 0.61; CI, 0.34-1.10), although this effect was
of borderline significance (P = .051) (Figure 6C,D).
Pharmacologic measurements and treatment outcome Median day 6 whole blood concentration of CsA, measured in 58 CsA patients, was 1774 ng/mL (range, 559-14 230, with 9 censored values reported as 1500+). Serum from 49 CsA patients significantly augmented ex vivo DNR cytotoxicity in Pgp-overexpressing 8226/Dox6 cells with a median sensitization factor of 5.7, compared to 2.2 in 70 controls (P = .0001). Adequate pharmacokinetic sampling was available from 145 patients for analysis of DNR or DNR-ol (or both) serum concentration. Although there was considerable individual variance in steady-state serum concentration of the anthracyclines, the median estimates of day 9 DNR (P = .0028) and DNR-ol (P < .0001) concentrations were significantly higher in CsA patients (Table 6). Elimination of the anthracycline species was rapid after termination of the CsA infusion. Nonetheless, day 10 DNR (P = .0005) and DNR-ol (P < .0001) serum concentrations remained significantly elevated in CsA patients.
Additional analyses were performed to investigate whether greater
systemic exposure to DNR-ol alone or an interaction with CsA might
explain the effects of CsA on outcomes (Table
7). CR rates improved with increasing day
9 DNR concentration in the CsA arm, but decreased slightly with
increasing DNR concentration among controls (interaction
P = .033). The analogous interaction of study treatment
and day 9 DNR-ol concentration on remission rate was not statistically
significant (P = .35). Similarly, the frequency of
resistance to induction therapy decreased with increasing DNR serum
concentration in CsA-treated patients, but not in controls (P = .078). A similar nonsignificant relationship was
detected between DNR-ol concentration and induction resistance
(P = .091).
Although there was no improvement in survival in relation to DNR
concentration among all study patients (P = .58), OS
improved with increasing day 9 serum DNR concentration in CsA-treated
patients, but decreased with increasing DNR concentration in controls
(interaction P = .0003; Figure
7A,B). Similar interactions with
treatment were detected for day 9 serum DNR-ol concentration in the
analysis of OS (P = .0068), and for day 9 serum DNR
concentration in the analysis of RFS (Figure 7C,D;
P = .062).
Treatment-related toxicity and mortality Three patients were excluded from the analysis of induction toxicity: one control died before initiating treatment, another erroneously received CsA, and one CsA patient did not receive protocol-directed therapy. Induction deaths occurred in 15% (CI, 9%-22%) of CsA patients and 18% (CI, 11%-25%) of controls. One CsA patient died of pulmonary hemorrhage, whereas infection was the cause of all other induction deaths. Grade 4 hyperbilirubinemia occurred with significantly greater frequency in the CsA-treated cohort (31% versus 4%, P < .0001). Except for hyperbilirubinemia, the frequency of grade 3+ nonhematologic toxicities was similar in the 2 treatment groups. Grade 3 nausea was more common in CsA patients (11%) than controls (3%; P = .016). There was no significant difference in the frequency or severity of stomatitis (CsA, 4%; controls, 8 grade 3), or renal toxicity as measured by
creatinine elevation (CsA, 2%; controls, 3%, grade 3).
In this randomized clinical trial, the coadministration of high-dose CsA with infusional DNR during induction and consolidation therapy significantly reduced the frequency of resistance to induction chemotherapy and the probability of leukemia relapse in remitting patients with poor-risk AML or RAEB-t. The estimated 2-year RFS of remitting CsA patients was 34%, compared to 9% for controls. Moreover, survival was significantly improved with CsA treatment, with estimated 2-year survival probability of 22% with CsA compared to 12% in the control group. Inhibition of Pgp transport function in preclinical models requires CsA concentrations ranging from 1000 to 2000 ng/mL.4-6 The median whole-blood CsA concentration of 1774 ng/mL achieved in this trial was within the targeted therapeutic range and was pharmacologically active as confirmed in the ex vivo cytotoxicity assay. Indeed, treatment with CsA extended median survival in patients with Pgp-overexpressing AML 3-fold (12 months versus 4 months), whereas no difference in median survival was evident in patients with absent or minimal Pgp expression. Similarly, the probability of survival was improved with CsA treatment when adjusted for cytogenetic pattern, with the benefit of study treatment extending to both previously treated and untreated patients. In addition to its inhibitory effect on the multidrug transporter Pgp, CsA like other cyclosporines, alters the hepatobiliary elimination of bilirubin and anthracyclines.13,30-32 Transient and sometimes extreme conjugated hyperbilirubinemia occurred with higher frequency in CsA-treated patients (31% versus 4%); however, sustained hepatic organ toxicity was uncommon. Although treatment with CsA approximately doubled the steady-state serum concentration of DNR, there was no associated increase in treatment-related toxicity as measured by the occurrence of congestive heart failure, mucositis, or induction deaths. The apparent equivalence in toxicities may relate in part to the extensive individual variation in DNR elimination and the prolonged schedule of DNR administration. A 24-hour infusion of DNR was used in this trial to optimize potentiation of anthracycline antileukemia activity in the presence of CsA. Preclinical investigations indicate that sensitization of multidrug-resistant tumor cells to anthracyclines or other natural products by Pgp antagonists is both concentration- and time-dependent, and is thereby optimized by prolonged exposure to the targeted antineoplastic.33-36 Extending the duration of DNR infusion attenuates peak serum concentration (Cmax), which in this trial remained considerably lower than the micromolar concentrations expected with bolus administration of conventional doses. These differences may account for the necessity for significant reduction in antineoplastic dosage in other trials testing cyclosporine modulators to obviate excessive toxicity when the anticancer drug is administered by bolus or rapid intravenous infusion. The notion that CsA improved treatment outcome by enhancing leukemia sensitivity to DNR rather than by simply increasing DNR exposure per se is supported by the relationship between steady-state serum DNR concentration and efficacy end points. The rate of CR increased and the frequency of resistance to induction therapy decreased with increasing DNR and DNR-ol serum concentration in CsA-treated patients, whereas a similar relationship was not observed in the control group. Analogous effects on RFS and OS were evident in CsA-treated patients; however, in contrast, survival inversely correlated with serum DNR concentration in the control group. If confirmed, these observations have important therapeutic implications for anthracycline therapy in AML. Steady-state serum DNR concentration may be a critical determinant of treatment outcome when the anthracycline is administered in the presence of a cell defense inhibitor such as CsA, whereas in its absence, greater systemic DNR exposure may contribute to an inferior outcome by increasing nonhematologic toxicity. This study represents the first randomized trial to demonstrate a significant clinical benefit of Pgp modulation in adults with AML, and more importantly, it is the first randomized cooperative group study using modern chemotherapy and supportive care to yield a significant improvement in survival in patients with poor-risk AML. A French cooperative group study compared remission induction therapy with mitoxantrone and cytarabine with or without the addition of the Pgp modulator, quinine sulfate.37 Although the addition of quinine conferred a nonsignificant reduction in the frequency of induction resistance, this study was limited by the heterogeneity in leukemia types and greater mucosal and cardiac toxicity in the quinine-treated group. The Medical Research Council (MRC) recently completed a randomized trial in older AML patients that compared 2 DNR- and etoposide-containing induction regimens with secondary randomization to the addition of CsA.38 This trial showed greater induction toxicity with CsA, but used a CsA dosage (5 mg/kg per day) insufficient for systemic blockade of Pgp transport function. In addition, the MRC trial included etoposide, an agent with low affinity for Pgp,39,40 and in both trials the targeted antineoplastic was administered by rapid intravenous infusion. These differences from the current study design suggest that both the schedule of antineoplastic administration and the selection of an antileukemia agent whose activity is limited by high affinity for Pgp are potentially important determinants of the success of modulator strategies in AML. Four randomized trials evaluating the more potent and selective, second-generation Pgp antagonist, PSC 833, were recently completed, but yielded disappointing results.39-42 Studies performed by the Eastern Cooperative Oncology Group (ECOG) and Cancer and Leukemia Group-B (CALGB) were prematurely suspended due to lack of benefit or excessive toxicity in the PSC 833-treatment cohorts, respectively.41-42 In each of these trials, the targeted antineoplastic(s) were administered by rapid infusion, necessitating dose reduction to accommodate average changes in drug elimination, thereby raising concern that anthracene underdosing undermined the potential for benefit in up to one third of patients in whom a pharmacokinetic interaction is not anticipated.43 Nevertheless, these trials raise the notion that CsA represents a potentially more effective modulator of chemotherapy resistance by virtue of its actions on alternate mechanisms of cell defense, in addition to Pgp. Indeed, CsA moderately enhances DNR retention and cytotoxicity in multidrug-resistant tumor cells that overexpress the ATP-binding cassette (ABC) transporters, multidrug-resistance protein-1 (MRP-1),44-46 or the recently described breast cancer- or mitoxantrone-resistance protein (BCRP, MXR, ABCp).47-48 In addition, through its interaction with cyclophilin, CsA suppresses angiogenic response to vascular endothelial growth factor,49 a cytokine implicated in myeloblast self-renewal and which carries adverse prognostic relevance in AML.50-52 It is plausible that the capacity for CsA to inhibit the above or other biologic targets that promote leukemia survival53-56 served to magnify the benefit of Pgp modulation in this study. Nevertheless, these data provide convincing evidence for the potential benefit of such Pgp-modulation strategies in patients with poor-risk AML.
We are indebted to many people who contributed to the success of this study, in particular Dr William Dalton for advice regarding study design, Dr Sheila Dobin for cytogenetic review, the many SWOG clinical investigators for their commitment to quality patient care, Ms Laura Kingsbury for her efforts in data coordination and evaluation, and to the late Dr Sydney Salmon, whose mentorship and intellectual advice were invaluable.
Submitted August 31, 2000; accepted July 18, 2001.
Supported in part by the following Public Health Service Cooperative Agreement grant numbers awarded by the National Cancer Institute, Department of Health and Human Services: CA38926, CA32102, CA13612, CA12213, CA46368, CA14028, CA35431, CA58416, CA20319, CA04919, CA46282, CA76448, CA58882, CA63845, CA76462, CA35261, CA46441, CA35176, CA12644, CA58686, CA46113, CA52654, CA35090, CA46136, CA35281, CA04920, CA58861, CA35192, CA45450, CA76447, CA42777, CA35178, CA67663, CA16385, CA45560, CA63850, CA35128, CA76132, CA96429, CA22433, CA58415.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Alan F. List, Southwest Oncology Group (SWOG-9126), Operations Office, 14980 Omicron Dr, San Antonio, TX 78245; e-mail: alist{at}azcc.arizona.edu.
1. Gerlach JH, Endicott JA, Juranka PF, et al. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature. 1986;324:485-489[CrossRef][Medline] [Order article via Infotrieve].
2.
Ng WF, Sarangi F, Zastawny RL, Veinot-Drebot L, Ling V.
Identification of members of the P-glycoprotein multigene family.
Mol Cell Biol.
1989;9:1224-1232
3.
Ueda K, Cardarelli C, Gottesman MM, Pastan I.
Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine.
Proc Natl Acad Sci U S A.
1987;84:3004-3008 4. Nooter K, Sonneveld P, Oostrum R, Herweijer H, Hagenbeek T, Valerio D. Overexpression of the mdr 1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A. Int J Cancer. 1990;45:263-268[Medline] [Order article via Infotrieve]. 5. Coley HM, Twentyman PR, Workman P. Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A. Biochem Pharmacol. 1989;38:4467-4475[CrossRef][Medline] [Order article via Infotrieve].
6.
Naito M, Tsuge H, Kuroko C, et al.
Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance.
J Natl Cancer Inst.
1993;85:311-316
7.
Pirker R, Wallner J, Geissler K, et al.
MDR1 gene expression and treatment outcome in acute myeloid leukemia.
J Natl Cancer Inst.
1991;83:708-712
8.
Campos L, Guyotat D, Archimbaud E, et al.
Clinical significance of multidrug resistance P-glycoprotein expression in acute nonlymphoblastic leukemia cells at diagnosis.
Blood.
1992;79:473-476 9. List AF, Spier CM, Cline A, et al. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. Br J Haematol. 1992;78:28-34.
10.
Leith CP, Kopecky KJ, Godwin J, et al.
Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study.
Blood.
1997;89:3323-3329 11. Samdani A, Vijapurkar U, Grimm MA, et al. Cytogenetics and P-glycoprotein (Pgp) are independent predictors of treatment outcome in acute myeloid leukemia (AML). Leuk Res. 1996;20:175-180[CrossRef][Medline] [Order article via Infotrieve]. 12. List AF. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia. 1996;10:937-942[Medline] [Order article via Infotrieve].
13.
List AF, Spier C, Greer J, et al.
Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.
J Clin Oncol.
1993;11:1652-1160 14. Bartlett NL, Lum BL, Fisher GA, et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol. 1994;12:835-842[Abstract]. 15. Cheson BD, Cassileth PS, Head DR, et al. Report of the National Cancer Institute-sponsored workshop of definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8:813-819[Abstract]. 16. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1995;31:103-115. 17. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 1992;10:239-253[CrossRef][Medline] [Order article via Infotrieve].
18.
Leith CP, Chen IM, Kopecky KJ, et al.
Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR1 19. Young IT. Proof without prejudice: Use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources. J Histochem Cytochem. 1977;25:935-941[Abstract]. 20. Peng YM, Alberts DS, Salmon SE, Davis TP. A method for the simultaneous measurement of the new anthracycline derivative 4'-deoxydoxorubicin and its metabolites by reversed phase liquid chromatography. Invest New Drugs. 1984;2:277-280[Medline] [Order article via Infotrieve]. 21. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63[CrossRef][Medline] [Order article via Infotrieve]. 22. Mitelman F, ed. ). An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1995.
23.
Schiffer CA, Lee Ej, Tomiyasu T, Wiernik PH, Testa JR.
Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia.
Blood.
1989;73:263-270 24. Fenaux P, Preudhomme C, Lai JL, Morel P, Beauscart R, Bauters F. Cytogenetics and their prognostic value in de novo acute myeloid leukemia: a report on 283 cases. Br J Haematol. 1989;73:61-67[Medline] [Order article via Infotrieve].
25.
Slovak ML, Kopecky KJ, Cassileth PA, et al.
for the Southwest Oncology and Eastern Oncology Cooperative Groups. Karyotypic analysis predicts outcome of pre- and post-remission therapy in adult acute myeloid leukemia (AML): a SWOG/ECOG intergroup study.
Blood.
2000;96:4075-4083 26. Dastugue N, Payen C, Lafage-Pochitaloff M, et al. Prognostic significance of karyotype in de novo adult myeloid leukemia. Leukemia. 1995;9:1491-1498[Medline] [Order article via Infotrieve]. 27. Cox DR. The Analysis of Binary Data. London United Kingdom: Chapman & Hall; 1970. 28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481[CrossRef]. 29. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-220.
30.
Kornblau SM, Estey E, Madden T, et al.
Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC 833 in relapsed or refractory acute myelogenous leukemia.
J Clin Oncol.
1997;15:1796-1802
31.
Booth CL, Brouwer KR, Brouwer KL.
Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver.
Cancer Res.
1998;58:3641-3648
32.
Lum BL, Kaubisch S, Yahanda AM, et al.
Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.
J Clin Oncol.
1992;10:1635-1642
33.
Cass CE, Janowska-Wieczorek A, Lynch MA, et al.
Effect of duration of exposure to verapamil on vincristine activity against multidrug-resistant human leukemic cell lines.
Cancer Res.
1989;49:5798-4804 34. Lai GM, Chen YN, Mickley LA, et al. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer. 1991;49:696-703[Medline] [Order article via Infotrieve].
35.
Slate D, Michelson S.
Drug resistance-reversal strategies: comparison of experimental data with model predictions.
J Natl Cancer Inst.
1991;83:1574-1580 36. Toffoli G, Tumiotto L, Gigante M, et al. Increased chemosensitivity to doxorubicin of intrinsically multidrug resistant human colon carcinoma cells by prolonged exposure to verapamil. Eur J Cancer. 1993;29A:1776-1778[CrossRef].
37.
Solary E, Witz B, Caillot D, et al.
Combination of quinine as a reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study.
Blood.
1996;88:1198-1205 38. Liu Tin JA, Wheatley K, Rees J, Burnett A. Comparison of two chemotherapy regimens with or without cyclosporine-A, in relapsed/refractory acute myeloid leukemia.: results of the UK Medical Research Council AML-R trial [abstract]. Blood. 1998;92:231a. 39. Politit PM, Arnold ST, Felsted RL, Sinha BK. P-glycoprotein-independent mechanism of resistance to VP-16 in multidrug-resistant tumor cell lines: pharmacokinetic and photoaffinity labeling studies. Mol Pharmacol. 1990;37:790-796[Abstract].
40.
Sehested M, Friche E, Jensen PB, Demant EJF.
Relationship of VP-16 to the classical multidrug resistance phenotype.
Cancer Res.
1992;52:2874-2879 41. Greenberg P, Advani R, Tallman M, et al. Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: randomized phase II trial (E2995) [abstract]. Blood. 1999;94:383a.
42.
Baer MR, George SL, Dodge RK, et al.
Phase III study of PSC833 modulation of multidrug resistance (MDR) in previously untreated acute myeloid leukemia (AML) patients 43. Dorr R, Karanes C, Spier C, et al. Phase I/II study of the p-glycoprotein modulator PSC 833 (valspodar) in patients with acute myeloid leukemia. J Clin Oncol. 2000. In press.
44.
Ross DD, Wooten PJ, Tong Y, et al.
Synergistic reversal of multidrug resistance phenotype in acute myeloid leukemia cells by cyclosporin A and Cremophor EL.
Blood.
1994;83:1337-1347
45.
Ross DD, Wooten PJ, Sridhara R, et al.
Enhancement of daunorubicin accumulation, retention and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia.
Blood.
1993;82:1288-1299
46.
Cole SPC, Sparks KE, Fraser K, et al.
Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells.
Cancer Res.
1994;54:5902-5910 47. Doyle LA, Ross D, Sridhara R, et al. Expression of a 95 kDa membrane protein is associated with low daunorubicin retention in leukemic blast cells. Br J Cancer. 1995;71:52-58[Medline] [Order article via Infotrieve].
48.
Doyle LA, Tang W, Abruzzo LV, et al.
A multidrug resistance transporter from human MCF-7 breast cancer cells.
Proc Natl Acad Sci U S A.
1998;95:15665-15670 49. Iurlaro M, Vacca A, Minischetti M, et al. Antiangiogenesis by cyclosporine. Exp Hematol. 1998;26:1215-1222[Medline] [Order article via Infotrieve].
50.
Bellamy WT, Richter L, Sirjani D, et al.
Vascular endothelial cell growth factor (VEGF) is an autocrine promoter of abnormal localized immature myeloid precursors (ALIP) and leukemia progenitor formation in myelodysplastic syndromes (MDS).
Blood.
2001;97:1427-1434
51.
Fiedler W, Graeven U, Ergun S, et al.
Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia.
Blood.
1997;89:1870-1875
52.
Aguayo A, Estey E, Kantarjian H, et al.
Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia.
Blood.
1999;94:3717-3721 53. Slater LM, Sweet P, Stupecky M, Gupta S. Cyclosporin-A reverses vincristine and daunorubicin resistance in acute lymphoblastic leukemia in vitro. J Clin Invest. 1986;77:1405-1408.
54.
Meador J, Sweet P, Stupecky M, et al.
Enhancement by cyclosporin A of daunorubicin efficacy in Ehrlich ascites carcinoma and murine hepatoma 129.
Cancer Res.
1987;47:6216-6219
55.
Ito C, Ribeiro RC, Behm FG, Raimondi SC, Pui CH, Campana D.
Cyclosporin A induces apoptosis in childhood acute lymphoblastic leukemia cells.
Blood.
1998;91:1001-1007
56.
List AF, Glinsmann-Gibson, Heaton R, Schlegel S, Guzman M, Futscher B.
Cyclosporines (CS) inhibit interleukin-1
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  P. S. Becker, K. J. Kopecky, A. N. Wilks, S. Chien, J. M. Harlan, C. L. Willman, S. H. Petersdorf, D. L. Stirewalt, T. Papayannopoulou, and F. R. Appelbaum Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia Blood, January 22, 2009; 113(4): 866 - 874. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Shah and J. E. Lancet Frontline Treatment of Acute Myeloid Leukemia: Are We Making Progress? ASCO Educational Book, January 1, 2009; 2009(1): 372 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Laubach and A. V. Rao Current and Emerging Strategies for the Management of Acute Myeloid Leukemia in the Elderly Oncologist, October 1, 2008; 13(10): 1097 - 1108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chumsri, W. Matsui, and A. M Burger Therapeutic Implications of Leukemic Stem Cell Pathways Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 397 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Stone Genetically Defined Prognostic Factors and Novel Therapeutics for AML ASCO Educational Book, January 1, 2008; 2008(1): 280 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chumsri, W. Matsui, and A. M. Burger Therapeutic Implications of Leukemic Stem Cell Pathways Clin. Cancer Res., November 15, 2007; 13(22): 6549 - 6554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Marchetti, R. Mazzanti, J. H. Beijnen, and J. H. M. Schellens Concise Review: Clinical Relevance of Drug Drug and Herb Drug Interactions Mediated by the ABC Transporter ABCB1 (MDR1, P-glycoprotein) Oncologist, August 1, 2007; 12(8): 927 - 941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Q. Xia, N. Liu, G. T. Miwa, and L.-S. Gan Interactions of Cyclosporin A with Breast Cancer Resistance Protein Drug Metab. Dispos., April 1, 2007; 35(4): 576 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. P. Erba Prognostic Factors in Elderly Patients with AML and the Implications for Treatment Hematology, January 1, 2007; 2007(1): 420 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yokota, S. Kimura, S. Masuda, E. Ashihara, J. Kuroda, K. Sato, Y. Kamitsuji, E. Kawata, Y. Deguchi, Y. Urasaki, et al. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity Blood, January 1, 2007; 109(1): 306 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Marzac, I. Teyssandier, O. Calendini, J.-Y. Perrot, A.-M. Faussat, R. Tang, N. Casadevall, J.-P. Marie, and O. Legrand Flt3 Internal Tandem Duplication and P-Glycoprotein Functionality in 171 Patients with Acute Myeloid Leukemia Clin. Cancer Res., December 1, 2006; 12(23): 7018 - 7024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Steinbach, J.-P. Gillet, A. Sauerbrey, B. Gruhn, K. Dawczynski, V. Bertholet, F. de Longueville, F. Zintl, J. Remacle, and T. Efferth ABCA3 as a Possible Cause of Drug Resistance in Childhood Acute Myeloid Leukemia. Clin. Cancer Res., July 15, 2006; 12(14): 4357 - 4363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Wilson, G. S. Davidson, S. B. Martin, E. Andries, J. Potter, R. Harvey, K. Ar, Y. Xu, K. J. Kopecky, D. P. Ankerst, et al. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction Blood, July 15, 2006; 108(2): 685 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Zwaan, M. L. den Boer, K. M. Kazemier, K. Hahlen, A. H. Loonen, D. Reinhardt, U. Creutzig, G. J. L. Kaspers, R. Pieters, G. V. Dahl, et al. Does modulation of P-glycoprotein have clinical relevance in pediatric acute myeloid leukemia? Blood, June 15, 2006; 107(12): 4975 - 4977. [Full Text] [PDF]
|
|
|
|
|
|
B. I. Sikic Multidrug resistance and stem cells in acute myeloid leukemia. Clin. Cancer Res., June 1, 2006; 12(11): 3231 - 3232. [Full Text] [PDF]
|
|
|
|
|
|
M. H.G.P. Raaijmakers, E. P.L.M. de Grouw, B. A. van der Reijden, T. J.M. de Witte, J. H. Jansen, and R. A.P. Raymakers ABCB1 Modulation Does Not Circumvent Drug Extrusion from Primitive Leukemic Progenitor Cells and May Preferentially Target Residual Normal Cells in Acute Myelogenous Leukemia. Clin. Cancer Res., June 1, 2006; 12(11): 3452 - 3458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. Wilson, C. H. Fraga, C. E. Fuller, C. Rodriguez-Galindo, J. Mancini, N. Hagedorn, M. L. Leggas, and C. F. Stewart Immunohistochemical detection of multidrug-resistant protein expression in retinoblastoma treated by primary enucleation. Invest. Ophthalmol. Vis. Sci., April 1, 2006; 47(4): 1269 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Becton, G. V. Dahl, Y. Ravindranath, M. N. Chang, F. G. Behm, S. C. Raimondi, D. R. Head, K. C. Stine, N. J. Lacayo, B. I. Sikic, et al. Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421 Blood, February 15, 2006; 107(4): 1315 - 1324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ravandi and Z. Estrov Eradication of Leukemia Stem Cells as a New Goal of Therapy in Leukemia Clin. Cancer Res., January 15, 2006; 12(2): 340 - 344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Stock Controversies in Treatment of AML: Case-based Discussion Hematology, January 1, 2006; 2006(1): 185 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Advani, B. L. Lum, G. A. Fisher, J. Halsey, D. L. Chin, C. D. Jacobs, and B. I. Sikic A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance Ann. Onc., December 1, 2005; 16(12): 1968 - 1973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Walter, J. L. Pirga, M. R. Cronk, S. Mayer, F. R. Appelbaum, and D. E. Banker PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism Blood, November 15, 2005; 106(10): 3584 - 3593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Benderra, A. M. Faussat, L. Sayada, J.-Y. Perrot, R. Tang, D. Chaoui, H. Morjani, C. Marzac, J.-P. Marie, and O. Legrand MRP3, BCRP, and P-Glycoprotein Activities are Prognostic Factors in Adult Acute Myeloid Leukemia Clin. Cancer Res., November 1, 2005; 11(21): 7764 - 7772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. van der Holt, B. Lowenberg, A. K. Burnett, W. U. Knauf, J. Shepherd, P. P. Piccaluga, G. J. Ossenkoppele, G. E. G. Verhoef, A. Ferrant, M. Crump, et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis Blood, October 15, 2005; 106(8): 2646 - 2654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Tallman, D. G. Gilliland, and J. M. Rowe Drug therapy for acute myeloid leukemia Blood, August 15, 2005; 106(4): 1154 - 1163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Qadir, K. L. O'Loughlin, S. M. Fricke, N. A. Williamson, W. R. Greco, H. Minderman, and M. R. Baer Cyclosporin A Is a Broad-Spectrum Multidrug Resistance Modulator Clin. Cancer Res., March 15, 2005; 11(6): 2320 - 2326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H.G.P. Raaijmakers, E. P.L.M. de Grouw, L. H.H. Heuver, B. A. van der Reijden, J. H. Jansen, R. J. Scheper, G. L. Scheffer, T. J.M. de Witte, and R. A.P. Raymakers Breast Cancer Resistance Protein in Drug Resistance of Primitive CD34+38- Cells in Acute Myeloid Leukemia Clin. Cancer Res., March 15, 2005; 11(6): 2436 - 2444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Benderra, A.-M. Faussat, L. Sayada, J.-Y. Perrot, D. Chaoui, J.-P. Marie, and O. Legrand Breast Cancer Resistance Protein and P-Glycoprotein in 149 Adult Acute Myeloid Leukemias Clin. Cancer Res., December 1, 2004; 10(23): 7896 - 7902. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Kolitz, S. L. George, R. K. Dodge, D. D. Hurd, B. L. Powell, S. L. Allen, E. Velez-Garcia, J. O. Moore, T. C. Shea, E. Hoke, et al. Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621 J. Clin. Oncol., November 1, 2004; 22(21): 4290 - 4301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Mahadevan and A. F. List Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies Blood, October 1, 2004; 104(7): 1940 - 1951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Walter, B. W. Raden, M. R. Cronk, I. D. Bernstein, F. R. Appelbaum, and D. E. Banker The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin Blood, June 1, 2004; 103(11): 4276 - 4284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. U. C. Sankatsing, J. H. Beijnen, A. H. Schinkel, J. M. A. Lange, and J. M. Prins P Glycoprotein in Human Immunodeficiency Virus Type 1 Infection and Therapy Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1073 - 1081. [Full Text] [PDF]
|
|
|
|
|
|
H. Minderman, K. L. O'Loughlin, L. Pendyala, and M. R. Baer VX-710 (Biricodar) Increases Drug Retention and Enhances Chemosensitivity in Resistant Cells Overexpressing P-Glycoprotein, Multidrug Resistance Protein, and Breast Cancer Resistance Protein Clin. Cancer Res., March 1, 2004; 10(5): 1826 - 1834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Stone, M. R. O'Donnell, and M. A. Sekeres Acute Myeloid Leukemia Hematology, January 1, 2004; 2004(1): 98 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Steinbach, S. Wittig, G. Cario, S. Viehmann, A. Mueller, B. Gruhn, R. Haefer, F. Zintl, and A. Sauerbrey The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype Blood, December 15, 2003; 102(13): 4493 - 4498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Unger, M. LeBlanc, J. J. Crowley, H. B. Grossman, R. B. Natale, A. J. Wozniak, J. R. Berenson, A. F. List, W. A. Peters III, R. C. Flanigan, et al. Estimating the Impact of New Clinical Trial Proven Cancer Therapy and Cancer Chemoprevention on Population Mortality: The Karnofsky Memorial Lecture J. Clin. Oncol., December 1, 2003; 21(90230): 246s - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Brooks, H. Minderman, K. L. O'Loughlin, P. Pera, I. Ojima, M. R. Baer, and R. J. Bernacki Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein Mol. Cancer Ther., November 1, 2003; 2(11): 1195 - 1205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Leonard, T. Fojo, and S. E. Bates The Role of ABC Transporters in Clinical Practice Oncologist, October 1, 2003; 8(5): 411 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Solary, B. Drenou, L. Campos, P. de Cremoux, F. Mugneret, P. Moreau, B. Lioure, A. Falkenrodt, B. Witz, M. Bernard, et al. Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia Blood, August 15, 2003; 102(4): 1202 - 1210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Walter, B. W. Raden, T. C. Hong, D. A. Flowers, I. D. Bernstein, and M. L. Linenberger Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells Blood, August 15, 2003; 102(4): 1466 - 1473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Lockhart, R. G. Tirona, and R. B. Kim Pharmacogenetics of ATP-binding Cassette Transporters in Cancer and Chemotherapy Mol. Cancer Ther., July 1, 2003; 2(7): 685 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Steinbach, J. Lengemann, A. Voigt, J. Hermann, F. Zintl, and A. Sauerbrey Response to Chemotherapy and Expression of the Genes Encoding the Multidrug Resistance-associated Proteins MRP2, MRP3, MRP4, MRP5, and SMRP in Childhood Acute Myeloid Leukemia Clin. Cancer Res., March 1, 2003; 9(3): 1083 - 1086. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Lowenberg, J. D. Griffin, and M. S. Tallman Acute Myeloid Leukemia and Acute Promyelocytic Leukemia Hematology, January 1, 2003; 2003(1): 82 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Mufti, A. F. List, S. D. Gore, and A. Y.L. Ho Myelodysplastic Syndrome Hematology, January 1, 2003; 2003(1): 176 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Stone The Difficult Problem of Acute Myeloid Leukemia in the Older Adult CA Cancer J Clin, November 1, 2002; 52(6): 363 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. F. List, K. J. Kopecky, C. L. Willman, D. R. Head, M. L. Slovak, D. Douer, S. R. Dakhil, and F. R. Appelbaum Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase Blood, August 13, 2002; 100(5): 1910 - 1912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Baer, S. L. George, R. K. Dodge, K. L. O'Loughlin, H. Minderman, M. A. Caligiuri, J. Anastasi, B. L. Powell, J. E. Kolitz, C. A. Schiffer, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720 Blood, July 30, 2002; 100(4): 1224 - 1232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. V. Beattie, P. J. Petruska, K. J. Kopecky, A. F. List, and F. R. Appelbaum Cyclosporine modulation in poor-risk acute myeloid leukemia Blood, June 17, 2002; 100(1): 366 - 367. [Full Text] [PDF]
|
|
|
|
|
|
F. J. Giles, A. Keating, A. H. Goldstone, I. Avivi, C. L. Willman, and H. M. Kantarjian Acute Myeloid Leukemia Hematology, January 1, 2002; 2002(1): 73 - 110. [Abstract] [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
55 years versus > 55
years) and disease type and randomly assigned to treatment with
cytarabine (AraC) 3 g/m2 daily administered on induction
days 1 to 5 by 3-hour intravenous infusion, followed by DNR 45 mg/m2 per day administered by continuous infusion on days 6 to 8, or the same regimen with CsA.
(L-1